Goldman Sachs Alternatives led a $115m Series B round in Triveni Bio.

Goldman Sachs Alternatives, a venture capital firm, led a $115m Series B round in Triveni Bio, a biotech company focused on antibody therapeutics for immunological and inflammatory disorders, with participation from Fidelity Management & Research Company, Deep Track Capital, Atlas Venture, Cormorant Asset Management, OrbiMed, Viking Global Investors, and Invus. "We look forward to supporting both programs through clinical proof-of-concept and beyond," Josh Richardson M.D., Goldman Sachs Alternatives Managing Director.